Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
207,440,936
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
27,027,940
-
Shares change
-
-1,421,012
-
Total reported value, excl. options
-
$990,522,973
-
Value change
-
-$72,172,854
-
Put/Call ratio
-
102%
-
Number of buys
-
58
-
Number of sells
-
-80
-
Price
-
$36.66
Significant Holders of Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) as of Q3 2019
199 filings reported holding ESPR - Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2019.
Esperion Therapeutics, Inc. - Common Stock, par value $0.001 per share (ESPR) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27,027,940 shares
of 207,440,936 outstanding shares and own 13% of the company stock.
Largest 10 shareholders include Bellevue Group AG (4,241,461 shares), Meditor Group Ltd (2,679,835 shares), VANGUARD GROUP INC (2,668,463 shares), Pentwater Capital Management LP (2,478,261 shares), BlackRock Inc. (2,115,163 shares), STATE STREET CORP (1,442,360 shares), BOXER CAPITAL, LLC (975,000 shares), CREDIT SUISSE AG/ (952,643 shares), Rhenman & Partners Asset Management AB (655,854 shares), and WASATCH ADVISORS INC (630,397 shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.